Medical Device | April 29, 2026
FDA okays AstraZeneca’s triple therapy Breztri for asthma
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The aim is to simplify and strengthen long-term control of airway disease through triple therapy in one device
The approval was driven by data from the Phase III TULIP-SC trial
Convenient subcutaneous option has potential to reach more patients with same clinical benefits as Saphnelo IV infusion
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Approval based on MIRACLE Phase III trial demonstrating a significant and clinically meaningful reduction in asthma exacerbations and improvement in asthma symptom control
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Subscribe To Our Newsletter & Stay Updated
